儿童伴原始细胞增多的骨髓增生异常综合征中UBTF-TD对维奈克拉/阿扎胞苷的敏感性
本文报告三例连续儿童UBTF-TD型MDS-EB患者,在同情用药基础上接受维奈克拉联合阿扎胞苷(ven/aza)28天周期治疗,作为异基因造血干细胞移植的桥接。治疗耐受良好,三例均获完全缓解且流式细胞术阴性,均成功桥接至清髓性移植,末次随访时无病且无移植物抗宿主病。生物学特征显示BCL2高表达、BCL2A1和MCL1低表达,HOXA和HOXB过表达,以及UBTF-TD髓系肿瘤独特的甲基化特征。
要点
- 三例儿童UBTF-TD型MDS-EB接受ven/aza 28天周期治疗均获完全缓解且流式阴性。
- ven/aza耐受良好,三例均成功桥接至清髓性异基因造血干细胞移植。
- 末次随访时三例均无病且无移植物抗宿主病。
核心结论
- 三例连续儿童UBTF-TD型MDS-EB患者对维奈克拉联合阿扎胞苷治疗有应答,均获完全缓解并桥接至清髓性异基因造血干细胞移植,末次随访无病且无移植物抗宿主病。
研究设计与样本
- 三例连续儿童UBTF-TD型MDS-EB患者在同情用药基础上接受维奈克拉联合阿扎胞苷(ven/aza)28天周期治疗,作为异基因造血干细胞移植的桥接。
主要发现
- 治疗耐受良好,三例患者均对ven/aza疗程有应答,获完全缓解且流式细胞术阴性。
- 三例患者均桥接至清髓性异基因造血干细胞移植,末次随访时均无病且无移植物抗宿主病。
- 生物学特征显示BCL2基因高表达,伴BCL2A1和MCL1低表达。
- HOXA和HOXB均过表达,且UBTF-TD髓系肿瘤患者具有独特的甲基化特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UBTF-TD has been reported in a significant percentage of childhood MDS-EB and has been associated with inferior survival compared to that of patients with the wild-type gene. We treated three consecutive pediatric patients affected by UBTF-TD MDS-EB with venetoclax and azacitidine (ven/aza) in combination as 28-day cycles on a compassionate use basis three consecutive pediatric patients affected by UBTF-TD MDS-EB as a bridge to allogeneic HSCT. Treatment with ven/aza was well-tolerated, and all patients responded to the ven/aza course, achieving CR with flow-cytometry negativity. All three patients were bridged to myeloablative HSCT. All patients are disease-free and graft-versus-host disease-free at last follow-up. Comprehensive biological characterization of the disease showed (i) high expression of the BCL2 gene, paralleled by a low expression of BCL2A1 and MCL1; (ii) overexpression of both HOXA and HOXB; and (iii) a distinct methylation signature of patients with UBTF-TD myeloid neoplasms.
引用
- Merli P, Masetti R, Pigazzi M, et al. Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF -TD to Venetoclax/Azacitidine. Am J Hematol. 2025. PMID: 40905566. doi:10.1002/ajh.70056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。